| A case control study of sarcosine as an early prostate cancer detection biomarker. |
26429735 |
BMC Urol |
| A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss: potential for a teachable moment. |
27431498 |
Prostate Cancer Prostatic Dis |
| A genome-wide association study of prostate cancer in Latinos. |
31226226 |
Int J Cancer |
| A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. |
23232570 |
Adv Anat Pathol |
| A simple-to-use method incorporating genomic markers into prostate cancer risk prediction tools facilitated future validation. |
25684153 |
J Clin Epidemiol |
| Active surveillance for prostate cancer. |
21119090 |
JAMA |
| Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing. |
25636657 |
J Urol |
| Addressing overdiagnosis and overtreatment in cancer: a prescription for change. |
24807866 |
Lancet Oncol |
| An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. |
21350221 |
J Natl Cancer Inst |
| Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. |
22846433 |
J Proteomics |
| Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. |
12394768 |
J Urol |
| Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. |
16622122 |
J Natl Cancer Inst |
| Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. |
16406987 |
J Urol |
| Association of chromosome 8q variants with prostate cancer risk in Caucasian and Hispanic men. |
19528667 |
Carcinogenesis |
| Association of polymorphisms in TGFB1 and prostate cancer prognosis. |
18082198 |
J Urol |
| Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. |
17908993 |
Clin Cancer Res |
| Biomarker-based methods for determining noncompliance in a prevention trial. |
12505245 |
Control Clin Trials |
| Biomarkers for prostate cancer detection. |
17936845 |
J Urol |
| Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. |
20142396 |
Am J Epidemiol |
| Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. |
20739049 |
Urology |
| Characterization of PacMetUT1, a recently isolated human prostate cancer cell line. |
18361412 |
Prostate |
| CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians. |
18544568 |
Carcinogenesis |
| Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization. |
16618725 |
Cancer Res |
| DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence. |
26332453 |
Prostate |
| Erectile dysfunction and subsequent cardiovascular disease. |
16414947 |
JAMA |
| External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. |
17169636 |
Urology |
| Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. |
17437804 |
J Urol |
| Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. |
25090603 |
JAMA |
| Future directions in the prevention of prostate cancer. |
24281061 |
Nat Rev Clin Oncol |
| Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. |
23476788 |
Prostate Cancer |
| Helicobacter Pylori Infection in Texas Hispanic and Non-Hispanic White Men: Implications for Gastric Cancer Risk Disparities. |
28413904 |
Am J Mens Health |
| Higher baseline dietary fat and fatty acid intake is associated with increased risk of incident prostate cancer in the SABOR study. |
30385837 |
Prostate Cancer Prostatic Dis |
| Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. |
27635949 |
Am J Surg Pathol |
| Improving patient prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators. |
25989018 |
J Biomed Inform |
| Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. |
29422418 |
Eur Urol Focus |
| Integrating the predictiveness of a marker with its performance as a classifier. |
17982157 |
Am J Epidemiol |
| Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening. |
25686543 |
J Urol |
| Is there a role for body mass index in the assessment of prostate cancer risk on biopsy? |
24747090 |
J Urol |
| Lack of disparity in lower urinary tract symptom severity between community-dwelling non-Hispanic white, Mexican-American, and African-American men. |
17445654 |
Urology |
| Limited PSA testing in indigent men in South Texas: an appropriate care or missing a prevention opportunity? |
22822113 |
Cancer Epidemiol Biomarkers Prev |
| Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins. |
29254211 |
Oncotarget |
| Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. |
25065737 |
Prostate |
| Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. |
15998892 |
JAMA |
| Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. |
25819722 |
Eur Urol |
| Predicting prostate cancer risk through incorporation of prostate cancer gene 3. |
18707724 |
J Urol |
| Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. |
17634486 |
J Clin Oncol |
| Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. |
15163773 |
N Engl J Med |
| Processing of voided urine for prostate cancer RNA biomarker analysis. |
26306723 |
Prostate |
| Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. |
21074193 |
J Urol |
| Prostate cancer detection strategies. |
16630521 |
Curr Urol Rep |
| Prostate cancer detection: a view of the future. |
21130561 |
Eur Urol |
| Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. |
24862395 |
Urology |
| Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. |
17991549 |
Urology |
| Prostate-specific antigen in the early detection of prostate cancer. |
17576986 |
CMAJ |
| Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies. |
17405989 |
J Natl Cancer Inst |
| Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. |
15329895 |
Cancer |
| Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. |
18030357 |
Neoplasia |
| Relationship of body mass index and prostate specific antigen in a population-based study. |
15082010 |
Urol Oncol |
| Rethinking screening for breast cancer and prostate cancer. |
19843904 |
JAMA |
| SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. |
18024530 |
Clin Chem |
| Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. |
19683737 |
J Urol |
| Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer. |
26979652 |
J Urol |
| Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. |
19475640 |
Prostate |
| Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. |
15258333 |
Dis Markers |
| Single and multigenic analysis of the association between variants in 12 steroid hormone metabolism genes and risk of prostate cancer. |
19505920 |
Cancer Epidemiol Biomarkers Prev |
| Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. |
20086112 |
Cancer Epidemiol Biomarkers Prev |
| Temporal changes in the clinical approach to diagnosing prostate cancer. |
23271768 |
J Natl Cancer Inst Monogr |
| The association of body mass index and prostate-specific antigen in a population-based study. |
15668913 |
Cancer |
| The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer. |
24296854 |
Cancer Epidemiol Biomarkers Prev |
| The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. |
15283893 |
Urol Oncol |
| The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers. |
23193062 |
Clin Chem |
| The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. |
23313212 |
J Urol |
| The Next Generation of Clinical Decision Making Tools: Development of a Real-Time Prediction Tool for Outcome of Prostate Biopsy in Response to a Continuously Evolving Prostate Cancer Landscape. |
25636656 |
J Urol |
| Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. |
27810448 |
J Urol |
| Total prostate specific antigen stability confirmed after long-term storage of serum at -80C. |
18550121 |
J Urol |
| Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. |
29117387 |
J Natl Cancer Inst |
| Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. |
23515404 |
Clin Cancer Res |
| Urine metabolomics analysis for kidney cancer detection and biomarker discovery. |
19008263 |
Mol Cell Proteomics |
| Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. |
19836788 |
J Urol |
| Validation of genome-wide prostate cancer associations in men of African descent. |
21071540 |
Cancer Epidemiol Biomarkers Prev |
| Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. |
31639607 |
Cancer Epidemiol |
| VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. |
18483391 |
Clin Cancer Res |
| What do the screening trials really tell us and where do we go from here? |
24725484 |
Urol Clin North Am |
| Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. |
19286205 |
J Urol |
